HIV

News

ViiV's campaign wants communication between women and healthcare workers about HIV to move beyond harmful stereotypes and 'risk' labels.

News

ViiV's injectable HIV PrEP Apretude will soon be an alternative for people in England and Wales who cannot use daily oral options.

News

Gilead gets EU approval for its twice-yearly PrEP product Yeytuo, another key step in building what it hopes will be a new HIV blockbuster.

News

The WHO has recommended Gilead's twice-yearly HIV PrEP drug lenacapavir, calling it 'transformational', but there are concerns about patient access.

News

Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?

News

A new way to deliver mRNA to T cells could allow HIV that is hiding away to be exposed and targeted with antiretroviral therapies, say scientists.